Kamada (NASDAQ:KMDA) Lowered to Buy at StockNews.com

Kamada (NASDAQ:KMDA) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Several other analysts have also weighed in on KMDA. Stifel Nicolaus started coverage on Kamada in a report on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th.

Kamada Stock Performance

Shares of KMDA opened at $5.72 on Tuesday. The company has a 50-day simple moving average of $5.52 and a 200-day simple moving average of $5.54. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53. The firm has a market capitalization of $328.79 million, a P/E ratio of 24.87 and a beta of 1.06.

Institutional Investors Weigh In On Kamada

Large investors have recently modified their holdings of the stock. Calton & Associates Inc. acquired a new stake in Kamada in the 4th quarter valued at $111,000. Y.D. More Investments Ltd lifted its holdings in shares of Kamada by 107.1% during the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 15,000 shares during the period. Aristides Capital LLC lifted its holdings in shares of Kamada by 41.6% during the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 16,635 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.